# HHS just unlocked 6 peptides. Here are the rules most sellers will break.

*Peptides.build · Updated October 28, 2026 · Web version: https://peptides.build/news/hhs-peptide-policy/*

## The short answer

On October 28, 2026, HHS said it will not take enforcement action against state-licensed 503A pharmacies and licensed physicians that compound six peptides (BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV) for patients with a prescription, as long as ten conditions are met. It is an interim policy, not FDA approval.

## Which peptides are covered, and in which form?

The policy covers one chemical form of each peptide, by specific routes only. Anything else, including a different salt or a nasal BPC-157, is outside it.

| Peptide | Form | Routes covered | At Peptides.build |
|---|---|---|---|
| BPC-157 | acetate | Injection (SC or IM), oral, topical | Prescribed here, from $158/mo: https://peptides.build/protocols/bpc-157/ |
| MOTS-c | acetate | Injection (SC or IM) | Prescribed here, from $158/mo: https://peptides.build/protocols/mots-c/ |
| Epitalon | acetate | Injection (SC or IM), intermittent courses | Prescribed here, from $158/mo: https://peptides.build/protocols/epitalon/ |
| TB-500 | acetate | Injection (SC or IM) | Not offered yet |
| Semax | free base | Intranasal only | Not offered yet |
| KPV | acetate | Oral and topical only | Not offered yet |

## How did we get here?

| Date | What happened |
|---|---|
| Sept 29, 2023 | FDA puts all six on its Category 2 list ("significant safety risks"). Pharmacies stop compounding them. |
| Apr 22, 2026 | FDA takes them off Category 2. On its own, that did not make them compoundable under 503A. |
| Jul 23 to 24, 2026 | FDA's Pharmacy Compounding Advisory Committee votes FOR all six and AGAINST a seventh, DSIP. FDA's drug center (CDER) had recommended against every one. |
| Oct 28, 2026 | HHS files the enforcement-discretion policy. Docket HHS-OASH-2026-0496, FR Doc 2026-22192. |
| Oct 30, 2026 | Official publication in the Federal Register. |
| About Nov 13, 2026 | Public comments close at regulations.gov. |
| Not scheduled | FDA rulemaking decides each peptide's permanent status. The interim policy ends for a peptide when that rule is final. |

HHS overrode its own scientists. For all six, CDER recommended against listing and the advisory committee voted in favor. HHS points to new lot-tested certificates of analysis from FDA-registered manufacturers, newly documented real-world use, and the policy's own safeguards. It also says the goal is to pull patients away from "research-use-only peptides supplied by foreign manufacturers".

## What are the 10 conditions?

1. **On the list.** One of the six peptides in Appendix A.
2. **Right form, right route.** The exact salt form and route in Appendix B.
3. **Tested raw ingredient.** From an FDA-registered (section 510) facility, with a certificate of analysis covering identity, purity, potency, endotoxins, heavy metals, microbes and residual solvents.
4. **Known maker.** The original manufacturer is FDA-registered, follows CGMP and is named on the certificate.
5. **Adverse-event reporting.** Serious events and quality issues go to FDA MedWatch and to the states, and the label says how to report.
6. **The label.** "This is a compounded drug product. Not for resale."
7. **One active ingredient.** No blends, no stacks.
8. **Oral needs proof.** Capsules need documented human bioavailability.
9. **Syringe only.** The only device allowed is an FDA 510(k)-cleared syringe. No pens.
10. **A real prescription.** Patient-specific, from a licensed clinician, under every other FD&C Act rule.

## Which 3 rules will most sellers break?

- **Blends.** Stacks that combine BPC-157 with TB-500, KPV or anything else fail the one-active-ingredient rule. HHS wants side effects traceable to one substance.
- **Pens.** The only device allowed is a 510(k)-cleared syringe. Pens and auto-injectors are outside the policy.
- **"Research use only" vials.** No prescription, no licensed pharmacy, no MedWatch reporting. These are exactly what the policy is designed to replace.

Peptides.build prescriptions are single-ingredient for the covered peptides, filled by a licensed US 503A pharmacy and arrive already reconstituted, labeled with the concentration and ready to draw. No powder, no BAC water, no math.

## How is a compounded peptide different from a research peptide?

| | FDA-approved drug | Compounded (HHS policy) | Research use only |
|---|---|---|---|
| FDA reviewed safety and effectiveness | Yes | No | No |
| Prescription | Required | Required, patient-specific | None ("not for human use") |
| Who makes it | FDA-inspected manufacturer | State-licensed 503A pharmacy | Unlicensed vendor, often overseas |
| Raw-material testing | Full FDA review | Lot certificate from a registered maker | Seller's own claim |
| Adverse-event reporting | Mandatory | Required (MedWatch) | None |
| Who mixes it | Manufacturer | The pharmacy | You, with BAC water |

## What does prescribed BPC-157 cost?

Competitor prices were published before the policy and checked October 14 to 15, 2026 by PeptideCareIndex. What each price includes varies by provider, so open each source before comparing.

| Provider | What you buy | Published price |
|---|---|---|
| **Peptides.build** | 6-month plan, already reconstituted | **$158/mo ($163 month to month)** |
| Pepti | Four-week fill | $209 to $299 per fill |
| Moonshot Medical | Monthly plan (in person) | $250 a month |
| Desert Mobile Medical | Monthly program | $399 a month plus a processing fee |
| Florida Surgery & Weight Loss Center | One-month program | From $449 incl. $99 consultation |
| Rx Peps Direct | One vial order | $134 per order ($39 review repeats) |
| Research-chemical sellers | Vial labeled "not for human use" | About $40 to $60, no prescription, no pharmacy |

## What does the policy not settle?

- **Safety and effectiveness.** FDA's scientists recommended against all six, citing limited human data. Much of the research is preclinical.
- **State law.** State pharmacy boards can still restrict these peptides.
- **Permanence.** HHS can withdraw the policy in whole or in part if a safety or quality problem appears.
- **Sport.** BPC-157 and TB-500 remain on the World Anti-Doping Agency prohibited list.

## FAQ

**Is BPC-157 legal in the US now?**
As of October 28, 2026, HHS says it will not take enforcement action against a licensed 503A pharmacy or physician compounding BPC-157 acetate for a patient with a prescription, if ten conditions are met. It is still not FDA-approved, and research-chemical BPC-157 is still not sold for human use.

**Which peptides does the HHS policy cover?**
Six: BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV. DSIP (emideltide) was voted down by the FDA advisory committee and is not covered.

**Are compounded peptides FDA-approved?**
No. Compounded medications are not FDA-approved, and the policy says it does not establish safety or effectiveness.

**Does the policy cover blends like BPC-157 with TB-500?**
No. The policy covers products with one active ingredient only.

**Can KPV or Semax be injected under the policy?**
No. KPV is covered for oral and topical use only, and Semax for intranasal use only.

**Do I still need a prescription?**
Yes. The policy requires a patient-specific prescription from a licensed clinician, filled by a state-licensed pharmacy.

**How long will the policy last?**
Until FDA issues a final rule for each peptide, or until HHS withdraws it. HHS can revisit it if a safety signal or quality problem appears. There is no fixed end date.

**How can I comment on the policy?**
At regulations.gov, docket HHS-OASH-2026-0496, until about November 13, 2026.

## Start a visit

A licensed US provider reviews a short online intake. If a prescription is appropriate, a US 503A pharmacy fills it and ships it already reconstituted.

- BPC-157: https://peptides.build/protocols/bpc-157/
- MOTS-c: https://peptides.build/protocols/mots-c/
- Epitalon: https://peptides.build/protocols/epitalon/

## Sources

- HHS policy with Appendices A and B: https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- Federal Register notice, FR Doc 2026-22192: https://public-inspection.federalregister.gov/2026-22192.pdf
- FDA, bulk drug substances used in compounding under section 503A: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- Hyman, Phelps & McNamara, FDA Law Blog (Oct 28, 2026): https://www.thefdalawblog.com/2026/10/the-peptide-l-wave-reaches-hhs-enforcement-discretion-not-the-finish-line/
- Reuters (Oct 28, 2026): https://www.reuters.com/legal/litigation/us-health-department-allow-temporary-sale-some-unapproved-peptides-2026-10-28/
- PeptideCareIndex BPC-157 cost survey: https://peptidecareindex.com/bpc-157-cost/

*This page is educational and is not medical advice. Compounded medications are not FDA-approved. No results are implied or guaranteed.*